Describe the risk factors for dysmenorrhea. Describe normal and abnormal physical examination findings on a pelvic exam. Discuss an appropriate differential diagnosis for a patient with dysmenorrhea. Describe the treatment of dysmenorrhea. Define menorrhagia. Discuss the evaluation of a patient with possible premenstrual syndrome (PMS). List the treatment options for a patient with premenstrual syndrome. Describe the use and insertion for the progestin only intrauterine device (IUD) in a patient with dysmenorrhea.

Using the attached Aquifer Case Study, answer the following questions using the latest evidenced based guidelines:

• Discuss the questions that would be important to include when interviewing a patient with this issue.
• Describe the clinical findings that may be present in a patient with this issue.
• Are there any diagnostic studies that should be ordered on this patient? Why?
• List the primary diagnosis and three differential diagnoses for this patient. Explain your reasoning for each.
• Discuss your management plan for this patient, including pharmacologic therapies, tests, patient education, referrals, and follow-ups.

Complete 2 pages

Provide references

Family Medicine 32: 33-year-old female with painful periods User: Alexander Chacon Ardite Email: alex911217@stu.southuniversity.edu Date: July 27, 2020 2:36AM

Learning Objectives

The student should be able to:

Describe the risk factors for dysmenorrhea. Describe normal and abnormal physical examination findings on a pelvic exam. Discuss an appropriate differential diagnosis for a patient with dysmenorrhea. Describe the treatment of dysmenorrhea. Define menorrhagia. Discuss the evaluation of a patient with possible premenstrual syndrome (PMS). List the treatment options for a patient with premenstrual syndrome. Describe the use and insertion for the progestin only intrauterine device (IUD) in a patient with dysmenorrhea.

Knowledge

Primary Dysmenorrhea Definition, Prevalence, and Risk Factors

Primary dysmenorrhea is defined as the onset of painful menses without pelvic pathology. Secondary dysmenorrhea is defined as painful menses secondary to some additional pathology. Primary dysmenorrhea is associated with increasing amounts of prostaglandins. The actual prevalence is unknown but ranges from 20% to 90%. Ten to fifteen percent of assigned females feel their symptoms are severe and have to miss school or work. Dysmenorrhea usually occurs hours to a day prior to the onset of menses and lasts up to 72 hours. Risk Factors for Primary Dysmenorrhea

Mood disorders such as depression or anxiety have been associated with dysmenorrhea, especially in adolescents. This may be a complex association as other factors may be comorbid with the mood disorder diagnosis, and the cause and effect is not well proven. However, there is an association with stress independently as a risk factor for dysmenorrhea. There is also an association between tobacco use and dysmenorrhea. Females who have more children are noted to have a decreased incidence of primary dysmenorrhea. Additionally, females who report overall lower state of health or other social stressors have a tendency for dysmenorrhea. These stressors include social, emotional, psychological, financial, or family stressors. Primary dysmenorrhea most commonly occurs in females in their teens and twenties. It is notably associated with ovulatory cycles. Classically, an adolescent will start experiencing dysmenorrhea one or two years after menarche. This is the time it takes naturally for an adolescent to develop regular ovulatory cycles. The earlier the onset of menarche the more likely dysmenorrhea may occur.

This means that a detailed history regarding the nature of menses during adolescence and after children is important. It will also be important to ask about birth control and what types have been used as some can alter the symptoms. The first-line treatment for primary dysmenorrhea is nonsteroidal anti-inflammatory agents, such as ibuprofen. Oral contraceptive pills may also be helpful as a second-line choice.

Gender

People who are born with a uterus may identify as female or male. We can therefore identify this population as “female assigned at birth,” meaning they had a sex assigned at birth as female based on the genitalia seen, or “person with a uterus” to acknowledge the biologic presence of a uterus in someone who may identify as anything other than female in their life. See below for additional gender Teaching Points.

Gender and Sexual Identity Questions

It is important to know how your patient self-identifies, and to not make assumptions. To avoid mis-gendering patients, we recommend asking early in a visit either how they would like to be addressed and/or what pronouns they use. Common answers are he/him, she/her, and they/them, but countless other pronouns exist within the LGBTQ community (lesbian, gay, bisexual, transgender, queer/questioning; this also includes a broad range of sexual, romantic, and gender minorities, and is more inclusively referred to as LGBTQIA with intersex and asexual/ally also represented). Cisgender refers to a person whose sex assigned at birth, based on genitalia, matches their current gender identity.

© 2020 Aquifer 1/9

Transgender refers to a person who identifies in a different way than their sex assigned at birth. The terms “assigned female” and “person with a uterus” acknowledge that this population may include people who have a uterus and periods who do not identify as female. Sex refers to the physical organs present or expect to develop at birth. Gender Identity refers to the patient’s identity as male, female, or non binary and is not the same as sex. Gender Expression refers to the patient’s presentation as male, female or nonbinary, and can be different from sex or gender identity. Non-binary, gender-nonconforming, and gender expansive are all terms some patients use to identify their gender as on a spectrum rather than binary. Sexual orientation refers to the gender that people have sex with. This can be different than romantic orientation as people can be romantically and sexually attracted to different genders, or vary based on the person or their own identity. For example, if a patient with a gynecological problem stated that they actually used he/him pronouns and identified as male, you would want to use he/him pronouns, despite talking about problems related to a uterus. You should not assume based on physical appearance what organs a patient may or may not have, in the same way that you cannot know without asking if someone has had a hysterectomy. For that purpose, we may refer to “people with a uterus” in this case to be more inclusive.

Questioning about Pregnancy History

It is good to start with open-ended questions. Some patients may have had pregnancy outcomes that they are not comfortable talking about, such as miscarriages or abortions (reported as SAB, or spontaneous abortion, or TAB, or therapeutic abortion). This requires sensitivity, as it may bring up trauma for that patient, and it may also require specific questions, such as “Tell me the outcomes of each pregnancy,” or “Any other pregnancies besides those children you mentioned?”

Normal Pelvic Exam Findings

Unless a person is pregnant, a normal uterus in not larger than eight weeks in size, approximately the size of a clenched fist. A normal uterus may be mildly tender on exam just prior to or during menses. A normal uterus can be tilted anteriorly (anteverted or anteflexed), midline, or tilted posteriorly (retroverted or retroflexed). An anteflexed or retroflexed uterus may be difficult to assess for size because of its position. The uterus should be smooth in contour around the entire surface area. Serosal fibroids or large mucosal fibroids may cause a “knobby” feel to the uterus. The uterus should be mobile. The uterus is held in the pelvis by a series of ligaments on each side. With endometriosis, the uterus may become nonmobile because of fibrous tissue sticking to the peritoneum along these ligaments. Ovaries are normally 2 cm x 3 cm in size—roughly the size of an oyster. In an obese female, the ovaries may be nonpalpable. During ovulation the ovaries may be slightly larger secondary to physiologic cysts. Caution should be taken while palpating the ovaries since the patient may have a mild sickening feeling. Mild tenderness on palpation of the ovaries is normal. Nabothian cysts are physiologically normal on the cervix. These are formed during the process of metaplasia where normal columnar glands are covered by squamous epithelium. They are merely inclusion cysts that may come and go and are of no clinical significance. While looking at the cervix white discharge can also normally be seen coming from the os or in the vagina. If there are endometrial growths on the cervix or vagina, these may be bluish. Vaginal discharge can be normal or abnormal. Normal vaginal discharge is termed physiologic leukorrhea. This patient has no symptoms like itching, burning, or foul-smelling discharge. It is normal to have physiologic clear to white vaginal discharge. The volume of discharge may get so heavy that it requires a pad for comfort; the volume may change during the course of a menstrual cycle.

Menorrhagia

Menorrhagia is very difficult to define precisely and is only one of the terms associated with abnormal uterine bleeding. The absolute criterion for menorrhagia is blood loss of more than 80 milliliters. Some providers try to use pad or tampon count. However, there is variability in the absorption of different pads and how much blood one has on the pad prior to changing. Asking about clots may help, but again not easy to quantify. In fact, many women either overestimate or underestimate the blood loss. Another important criterion is the length of menses. Anything longer than seven days is most likely menorrhagia.

Metrorrhagia is irregular frequent bleeding but it doesn’t have to be heavy. Menometrorrhagia that is irregular frequent and heavy bleeding.

Premenstrual Dysphoric Disorder DSM-5 Diagnostic Criteria

PMS is characterized by physical and behavioral symptoms occurring in the luteal phase of the normal menstrual cycle. Symptoms must not be present at other times through the cycle, and must also cause significant impairment. Premenstrual Dysphoric Disorder (PMDD), the more severe form of the disorder, is classified in the DSM-5 as a mental disorder. The patient must have one of the following: marked mood lability, irritability or anger, depressed mood or feeling hopeless, or anxiety and edginess. The patient must also have one of the following: food cravings, changes in sleep, a sense of being overwhelmed or out of control, decreased energy, anhedonia, and some physical symptoms.

© 2020 Aquifer 2/9

The patient must have a minimum of five symptoms out of the above groups. How these are expressed may differ based on culture and social norms. It may be helpful to get the perspective of other close contacts of the patient.

Preconception Counseling

Never lose a chance to bring up preconception considerations. 1. Vitamin supplementation: Daily supplementation with 400 to 800 micrograms of folic acid is recommended, as many

pregnancies are unplanned. This lowers the risk for neural tube defects by over 70%. Patients with a history of miscarriage or fetuses affected by neural tube defects should be counseled to take a higher dose.

2. Substance use: Substances such as alcohol, tobacco, caffeine, or other substances (marijuana, opioids, stimulants, etc.) should be discontinued (or, in the case of caffeine, at least cut back). Evidence is growing that marijuana can have detrimental effects on the fetus, even though it is more widely accepted. We recommend a sensitive approach to help patients with addiction cut down on substances when they are ready.

3. Immunizations: Check for immunizations that must be given prior to pregnancy because they are live, such as MMR and chickenpox. Guidelines suggest Tdap during each pregnancy, influenza if indicated by time of year, and testing for rubella immunity if there is not clear evidence of vaccination with the MMR vaccine.

4. Chronic conditions: Get any chronic medical problems—such diabetes, depression, asthma/COPD, or thyroid disorders— under control prior to pregnancy.

Safety and Mental Health

Premenstrual syndrome or premenstrual dysphoric disorder may coexist with additional Axis 1 and Axis 2 mental health diagnoses. Depression, anxiety, bipolar disorder, and additional psychiatric diagnoses should be considered, and if concerned, asking about thoughts or plans to harm oneself or another (suicidal ideation, homicidal ideation, and/or self harm or intent) is important.

Management

Primary Dysmenorrhea: Presentation and Treatment

In a family physician’s office, primary dysmenorrhea in an adolescent is a common diagnosis. In a person with a uterus who is under 20 and not sexually active with the classic history of suprapubic pain the first two days of menses, non-steroidal anti-inflammatory medications can be started without a pelvic exam. Ibuprofen is the gold-standard anti-inflammatory, but many other anti-inflammatories have also been proven equally efficacious when taken cyclically starting a day or two prior to the onset of menses and continuing into the first days of menses. Choice of the specific anti-inflammatory to use should be based on cost and side effects the patient experiences. If anti- inflammatories are not effective, combination birth control pills (monophasic or triphasic) with medium-dose estrogen are effective. Some people will prefer to avoid hormonal options if possible. A pregnancy test should be performed in an adolescent or anyone with a uterus who is sexually active with someone who has a penis. Other testing should be added if the patient has any type of dysfunctional uterine bleeding or pelvic pain outside of the typical pattern. For instance, consideration of polycystic ovary syndrome may be considered for irregular menstruation.

Treatment for Leiomyomas and Associated Symptoms

A Progesterone-releasing intrauterine device (IUD) is an effective option for reducing menstrual blood flow in those with menorrhagia secondary to fibroids. Another advantage is that it can be left in for five years (potentially longer but not yet widely accepted yet). There are potential complications, particularly during the procedure to place the device, but after appropriately discussing these with a patient it is a viable option. In studies, the progesterone-releasing IUD (levonorgestrel-releasing intrauterine system) has clearly demonstrated decreased menstrual flow in those with fibroids. In one smaller study, the device decreased overall uterine volume. However, it does not decrease the size of individual fibroids already in the uterus. Through decreasing uterine volume and endometrial atrophy, the progesterone-releasing IUD can also decrease dysmenorrhea. In people who hope to maintain fertility for the future yet control their symptoms now, this is one of the best options with fewest side effects. Irregular vaginal bleeding, especially initially, is a common side effect of the progesterone-releasing IUD. Other potential side effects are lower abdominal pain and breast tenderness. The risk of uterine perforation is more likely at the time of insertion. The risk of infection is within the first 20 days of insertion. Routine STI testing may be performed prior to or during insertion with immediate treatment if any infection is found. Good patient instructions to monitor for foul smelling discharge and signs of systemic infection or perforation are key. Acupuncture has been used for many pain conditions. Some studies demonstrate effectiveness for dysmenorrhea without uterine pathology when compared to sham or placebo treatments. In further studies, acupuncture improves quality of life but may be associated with higher health costs for the patient. Other nonmedical and nonsurgical treatment considerations for dysmenorrhea include TENS unit (transcutaneous electric nerve stimulation), thiamine supplementation, and, possibly, vitamin E supplementation. These may be offered to patients who are opposed to other treatments or in combination with other medical treatments. Combined hormonal contraceptives would be an effective option if the patient has not experienced side effects from these in the past. Oral contraceptive pills (OCPs) have been proven effective when used for dysmenorrhea related to anovulation only without a structural problem, especially in a patient who needs birth control. In those with isolated dysmenorrhea, small trials

© 2020 Aquifer 3/9

have demonstrated benefit. However, a meta-analysis of these found insufficient evidence that oral combined hormonal pills are effective for dysmenorrhea alone. The confusion is that OCPs are often used in structural problems of the uterus that cause both menorrhagia and dysmenorrhea. In leiomyoma and adenomyosis, OCPs decrease blood loss and may decrease dysmenorrhea by thinning the endometrial lining. OCPs are commonly known to patients and providers making them often the initial step in management. In adolescents, they have the additional benefit of regulated menses. However, other options that are not oral, such as the vaginal ring ring and the hormonal patch, are worth considering. These may cause less nausea and vomiting as they bypass the gastrointestinal system altogether. All types of combined hormonal contraceptives have slightly increased risk of venous thromboembolism, highest in the first year of use. For this reason, these types are not recommended in smokers older than 35 years. Specific side effects with the patch may be site dermatitis in as many as 20% of users. The vaginal ring has risks of leukorrhea and vaginitis in approximately 5% of patients; the other types do not. None of these worsen cervical dysplasia or have been proven to increase the risk of breast cancer. Injectable medroxyprogesterone is another potential treatment for leiomyomas and the symptoms associated with them. However, recent literature does demonstrate that there is bone density loss after several years of use. Other side effects may include weight gain, irregular menses for weeks to months, and potential mood changes. However, there is no risk of venous thromboembolism and this can be used in a smoker older than 35. This is a great choice for transgender men as it can help decrease periods without additional estrogen or a traumatizing procedure. Hysterectomy is the definitive surgical option for those with secondary dysmenorrhea and those with menorrhagia who no longer desire to bear children. In a meta-analysis, surgery has been proven to reduce bleeding more at one year than any other medical treatment. However, medical treatments may have less morbidity depending on the exact etiology of menorrhagia. Some surgeons will offer hysterectomy to a person with a uterus 14 to 16 weeks in size or greater whether or not the patient has symptoms. Any leiomyoma that is growing rapidly, regardless of the rest of the uterine exam, may be an indication for hysterectomy. For a patient who has failed other management, hysterectomy may be an option. Myomectomy, in which the clinician removes the leiomyoma but not the entire uterus, is another surgical option. Consideration of a patient’s future reproductive plans are important in distinguishing these two options. Other procedural options for dysmenorrhea unrelated to uterine pathology include presacral neurectomy and uterine nerve ablation, both via laparoscopy, though there is insufficient evidence to recommend those in most cases. The copper IUD is another effective form of birth control. This device may stay inside the uterus for up to 10 years. For those who are not planning any children in the near future, this may be a viable option for birth control. An advantage of the copper IUD is that it has no hormones. However, in people using this, there is an increased risk of dysmenorrhea and menorrhagia just from the IUD. It is not a treatment for leiomyomas at all. In this case it could potentially make the symptoms worse. Since all patients undergoing uterine artery embolization must understand the potential for urgent hysterectomy, consideration of future fertility is imperative. Some consider this a relative contraindication. Post procedure, the patient usually has pelvic pain for at least 24 hours, sometimes lasting up to 14 days. “Post-embolization syndrome” is a group of signs and symptoms that include pain, cramping, vomiting, fatigue, and sometimes fever and leukocytosis. Other complications from the procedure to consider as you counsel this patient are potential ovarian failure (up to 3% in women younger than 45), infection, necrosis of fibroids, and vaginal discharge and bleeding for up to two weeks. This treatment is usually reserved for those who cannot tolerate other hormonal treatments or who do not want those treatments for other reasons. This procedure is usually performed by an interventional radiologist. It is not an option for dysmenorrhea alone or for menorrhagia without uterine fibroids.

Hormonal Birth Control Therapies

Progesterone-Only Intrauterine Device (IUD)

The progesterone-only IUD can stay in place for three to seven years, depending on which device is used. There may be some irregular bleeding at the beginning for up to six months. Some women will stop bleeding altogether, and others continue having periods with less bleeding. The IUD is just taken out if the patient decides to try to get pregnant again. If, after five years, they decide they do not want to get pregnant, it can be replaced at the same visit for another five years. Progestin Implants

These are put under the skin and last for three years. They can cause unpredictable spotting and can also be removed earlier if desired. Hormone Patch

The patch is left in place for one week, then the person uses a new patch weekly for three weeks. No patch is placed during the fourth week, during which time the person has a period. This option contains ethinyl estradiol in addition to a progestin. Medroxyprogesterone Shot

The shot is given every 12 weeks. If a patient on this decides to get pregnant, it may take a little longer to get pregnant after stopping the shots than if they used the IUD. It also has a higher rate of irregular bleeding at the beginning. Vaginal Ring

The vaginal ring is placed inside the vagina and left for three weeks. It is removed the fourth week to have a period.

Premenstrual Syndrome Treatment

Danazol is an androgenic medication with progesterone effects. It lowers estrogen and inhibits ovulation. However, its multiple androgenic side effects, including weight gain, suppressing high density lipids, and hirsutism, limit its desirability among patients. GnRH agonists, such as leuprolide, are effective at treating premenstrual syndrome through ovulation inhibition. However, their anti-estrogen effects, including hot flashes and vaginal dryness, make these not as popular. Oral contraceptives are effective treatment for dysmenorrhea, anovulation, and in some cases menorrhagia. While not always effective for premenstrual syndrome, they are a good place to start. It would be appropriate to try this in a person also needing

© 2020 Aquifer 4/9

birth control. One study demonstrates potential improved effectiveness by decreasing the placebo pills to four days from seven. Additionally, pills can be taken for sequential cycles, skipping the placebo week, to reduce the frequency of menstruation and, theoretically, the rate of PMS/PMDD. Selective serotonin reuptake inhibitors (SSRI) during menses are an effective treatment of PMS, especially if severe mood symptoms predominate. There are three effective regimens for SSRI use. One regimen is continuous daily treatment. Another is intermittent treatment, which is just as effective as daily treatment for decreasing both psychological and physical symptoms during menses. There are two types of intermittent treatment. One method is to start therapy 14 days prior to menses (luteal phase of cycle) and continue until menses starts. The second method is to start on the first day a patient has symptoms and continue until the start of menses or three days later. Many randomized trials have used fluoxetine and sertraline. Venlafaxine can be used as well. Lower doses are effective. If one medication does not work, another in the same class should be tried prior to considering the treatment a failure. Follow-up should occur after two to four cycles. Intermittent treatment is associated with fewer side effects and lower cost. Hysterectomy is not effective for premenstrual syndrome as it does not alter hormonal balance in people with a uterus. Oophorectomy, however, is a potential surgical treatment for severe refractory cases in those done with childbearing. Spironolactone is a diuretic. It has been tested mainly to control symptoms such as bloating, weight gain, and breast tenderness. In studies, the effectiveness for treating these symptoms is inconsistent. It has anti-androgenic effects but offers less control than hormonal options. If this were to be tried on a patient, the dosing would be during luteal phase. One must be cautious about causing potential electrolyte abnormalities, such as hyperkalemia, with this medication. Vitamin B6 has inconsistent data regarding effectiveness. It may be effective for mild symptoms or in women reluctant to use antidepressants. Patients should be cautioned about overdosing as this may cause peripheral neurotoxicity. Other non-drug interventions include regular exercise and low carbohydrate diets. Decreasing carbohydrates in the luteal phase may be effective for mild symptoms. Relaxation therapy has also been studied and shown some efficacy. These are all worth discussing with patients, although true efficacy is not proven.

Progesterone-Releasing IUD Placement: Contraindications / Complications

Contraindications: Infection or active gynecologic cancer, allergy to levonorgestrel (uncommon) Cautions: History of headache or vascular disease, history of perforation with prior IUD placement, allergy to iodine or shellfish (often used to clean the cervix, other methods could be used). Complications:

During the actual procedure, the patient can have pain or bleeding. There is also a risk of a uterine infection or perforation. Both of these are rare. After the procedure is done, the patient may have some bleeding or cramping for a few days, but this usually responds to ibuprofen. There may be foul smelling vaginal discharge from an infection. Once the IUD in place, there is a risk the uterus can expel it, or the patient may have pain with intercourse or experience irregular bleeding. Some partners can feel the string. After the patient’s next period, she should come back to have the string checked and make sure it is still in place. It is a good idea for the patient to check for the IUD strings after every menses to ensure it stays inside the uterus but to use caution that it is not inadvertently removed. The strings can be trimmed at follow-up visits if needed. The patient should return to the clinic for any fever associated with lower abdominal pain, with or without abnormal vaginal discharge. These signs would be concerning for uterine infection.

Studies

Evaluation of Differential of Secondary Dysmenorrhea / Menorrhagia

A complete blood count is always a consideration when a person seems to be bleeding more heavily than usual. Iron deficiency anemia is common in patients of reproductive age, affecting between 21% and 67% of those with menorrhagia. It can add to the fatigue a person feels. This type of anemia is responsive to therapy, which initially is oral iron supplementation and could progress to iron infusions if indicated. A pregnancy test should be done on every person with a uterus of reproductive age with any changes in bleeding pattern or amount. Ectopic pregnancy can present with irregular bleeding and is life-threatening. Additionally, unusual forms of pregnancy— such as molar pregnancies—can cause heavy bleeding, abdominal pain, and uterine enlargement. Although it is acknowledged that pregnancy most commonly causes amenorrhea, these are diagnoses not to be missed. Ultrasound is the study of choice for pelvic pathology. The sensitivity is 60% and specificity is 93% for detecting intracavitary issues. The sensitivity for detecting intramural pathology is also high, but not as high as it is for detecting intracavitary issues. Ultrasound has a high positive predictive value for detecting adenomyosis as well. It does not require any radiation to the ovaries (CT scans will), no intravenous dyes are needed, and it is generally painless for the patient. The pelvic ultrasound does require an intravaginal portion, and all should be advised of this in advance. This could be uncomfortable and can cause psychological distress if the patient does not realize this will be done or if they have a history of trauma, particularly sexual trauma. The combination of abdominal and vaginal ultrasounds allow for reliable measurements and anatomy of the cervix, uterus, and ovaries. Ultrasound is acceptable at the initial evaluation whenever the physician thinks the patient has secondary dysmenorrhea based on clinical history and physical exam. Thyroid disorders are easy to check for and easy to treat. The fatigue and bowel symptoms of thyroid disease may also overlap with menstrual disorders, making the diagnosis easy to miss unless you are looking for it. Thyroid disorders can also affect the

© 2020 Aquifer 5/9

frequency of menses and should be considered if other causes of abnormal bleeding are excluded. Hypothyroidism is common in people of reproductive age, particularly those assigned female at birth. The American College of Obstetrics and Gynecology has not recommended this test for all initially without compelling history. However, guidelines from the United Kingdom do recommend thyroid testing. Computed tomography (CT) scans have been studied but these do not give a well-defined look at pelvic pathology and are not routinely used for gynecologic problems. They may be used at the end of a work-up for pelvic pain, but usually to look for other, non-gynecologic abdominal causes. Magnetic resonance imaging (MRI) is being used more often in diagnosing gynecologic pathology. It can give a better diagnosis of adenomyosis and locations of leiomyomas. MRI is able to more accurately assess changes in tumor volume preoperatively. At times it can provide better analysis of ovarian masses as well. MRI is expensive and time-consuming, factors that must be balanced with how useful the information obtained will be. MRI is not used as an initial study for secondary dysmenorrhea or menorrhagia. Testing for von Willebrand disease should be considered in any person with menorrhagia and other potential episodes of heavy bleeding, such as postpartum hemorrhage. In the initial workup of isolated dysmenorrhea, this is not recommended. However, when dysmenorrhea is present with menorrhagia it should be considered. Even though the American College of Obstetrics and Gynecology recommends testing for von Willebrand for any women with severe menorrhagia, meta-analyses do not demonstrate this to be cost-effective in initial assessment. The one exception is when menorrhagia occurs in an adolescent. Bleeding disorders more commonly present as menorrhagia from the beginning of menses rather than starting 15 years after menarche. If considering starting OCPs in an adolescent, one should order the von Willebrand prior to initiation, as it may affect the results.

Clinical Reasoning

Differential of Secondary Dysmenorrhea / Menorrhagia

More Common Diagnoses:

Adenomyosis

Epidemiology: Occurs more frequently in parous than nonparous people. Adenomyosis actually can be found in any person with a uterus from adolescence to menopause.

Pathophysiology: This is not completely understood. One theory is endometrial invagination, but has not been completely proven It is hypothesized that estrogen and progesterone play a role only because hormones can be treatment options.

Presentation: 60% of women complain of menorrhagia. The uterus is typically enlarged and diffusely boggy, but symmetric and should still be mobile. There may be some urinary or gastrointestinal symptoms secondary to size and mass effect on the bladder and rectum.

Diagnosis: Ultrasound may demonstrate a heterogeneously boggy uterus. MRI is more specific for diagnosis.

Management: There is not currently any surgical method to remove the discrete areas affected. Hormonal contraception may help with symptoms in those who desire future pregnancy, while uterine artery embolization or hysterectomy may be performed in those no longer desiring biological children.

Chronic pelvic inflammatory disease (PID)

Epidemiology: The exact incidence and prevalence is unknown.

Pathophysiology: PID can have a subclinical smoldering course that is considered chronic. These patients can have significant morbidities to include infertility and pain in the lower abdomen. Many of these cases will have plasma cells on endometrial biopsy.

Presentation: The cardinal symptom is lower abdominal pain, usually unrelated to menses. However, pain that occurs just prior to or during menses is highly suggestive of dysmenorrhea. Menorrhagia is seen in one-third of patients with chronic pelvic inflammatory disease, especially subclinical disease that isn’t treated early.

Management: As with acute PID, work up should include testing for sexually transmitted infections and treatment covering chlamydia and gonorrhea if suspected or diagnosed.

Endometriosis

Epidemiology: Endometriosis is a disorder that affects people of reproductive age with a uterus. The most common age affected is 25 to 35 years old. The exact prevalence in the general population is unknown. Risk factors include nulliparity, early menarche or late menopause, short menstrual cycles, and long menses. There may be protective factors that decrease the likelihood of endometriosis. These include multiparity, lactating, and late menarche.

Pathophysiology: Endometrial glands in areas other than the uterus.

Presentation: Symptoms include dyspareunia, bowel or bladder symptoms that cycle with menses, fatigue, abnormal vaginal bleeding, and some effects on fertility. Pain, either chronic pelvic pain or dysmenorrhea, occurs in 75% of patients with endometriosis and is the most common symptom. Dyspareunia is a differentiating clinical factor: it is common in those with endometriosis; it is rare with leiomyoma. On physical exam these patients have pain in the pain cul-de-sac, immobile and retroflexed

© 2020 Aquifer 6/9

uterus, nodules on the uterosacral ligaments, or just pain with uterine motion.

Management: Symptoms may be controlled with methods similar to those for menorrhagia. Hormonal contraceptives may alleviate symptoms. Hysterectomy and uterine artery embolization are less likely to be effective as the tissue is outside of the uterus.

Uterine leiomyomas

(commonly called fibroids)

Epidemiology: Fibroids are the most common benign tumors of the uterus. Decreased risk of developing fibroids has been noted with oral contraceptive use, increasing parity, and smoking. Increased risk is known with early menarche, family history of fibroids, and increased alcohol use. Although more research needs to be done exploring the causes of fibroids that include a more racially diverse pool, there seems to be a disproportionately high rate of fibroid development in African American women as compared to other racial demographic groups. Disparities also exist in the type of care that women receive for their fibroids; for example, studies have shown that Caucasian women are more likely to be offered a laparoscopic procedure as compared to African American and Hispanic women with the same household income, indicating systemic disparities in care.

Pathophysiology: These are made of normal myometrial cells. They can occur within the cavity and under the endometrium (submucosal), within the myometrium (intramural), on the serosal surface (serosal), or in the cervix.

Presentation: Common symptoms of fibroids include pain, pressure, and changes in menstruation. Other related signs may be miscarriages, infertility, or an enlarged uterus, and some may have no symptoms at all. Work loss and quality of life can be issues. The physical exam typically has an enlarged uterus that is freely mobile. The uterus may feel “knobby” from an irregular contour, and occasionally be minimally tender on exam.

Management: NSAIDS, combined oral contraceptive pills, levonorgestrel-releasing IUDs, depo- medroxyprogesterone, and a variety of surgical options (e.g., hysterectomy, myomectomy) are among the options.

Less Common Diagnoses:

Cervical stenosis

Cervical stenosis can be congenital or acquired. With congenital stenosis an adolescent will have significant dysmenorrhea, which is not as responsive to nonsteroidal anti-inflammatory medications as would be expected. The menstrual flow will also be minimal. Acquired stenosis may be related to cryotherapy or LEEP procedures (performed for concerns of cervical cancer on Pap tests and colposcopy biopsies). This causes dysmenorrhea as the uterus is distended with blood. On exam the uterus will feel diffusely enlarged.

Endometrial cancer

Endometrial cancer may occur under age 40 (2%–14% of cases), making this less likely. It does present with irregular bleeding, usually as postmenopausal bleeding. It may or may not cause dysmenorrhea.

Inflammatory bowel disease

Inflammatory bowel disease can often be misdiagnosed as a gynecologic problem since constipation and diarrhea are associated with premenstrual syndrome as well. Additionally, when a person has bloody stools during her menses, the clinical diagnosis can be more confusing. However, when there is pain with defecation and bloody stools occur at times other than during menses this diagnosis becomes clearer. Abnormal vaginal bleeding is not a typical symptom of inflammatory bowel disease.

Irritable bowel syndrome

Irritable bowel syndrome may cause crampy pain prior to and during menses, but will also occur at other times during the month. This pain is often associated with diarrhea and/or constipation.

Leiomyosarcoma Leiomyosarcoma is an abnormal variant of a smooth muscle tumor that can occur anywhere in the bodybut is commonly in the abdomen. It is a rare type of cancer and therefore less likely.

Ovarian cysts Ovarian cysts commonly cause recurrent and chronic pelvic pain. This type of pain is more likely to occur mid-cycle, although the patient may have pain associated with menses. This location of this pain is typically in one of the lower quadrants and not as much midline. Ovarian cysts may come and go related to ovulation.

Mood disorders or adjustment disorders

Mood disorders or adjustment disorders can be exacerbated by, but do not typically cause, dysmenorrhea. Dysmenorrhea is a real pain syndrome. If you treat a concurrent mood disorder it can improve the pain response.

Uterine polyps Uterine polyps may be associated with abnormal bleeding—specifically intermenstrual or postcoital bleeding—but there will also be menorrhagia. Polyps do not typically present with dysmenorrhea, but this may occur later.

References

© 2020 Aquifer 7/9

ACOG Committee on Practice Bulletin – Gynecology. ACOG practice bulletin: management of anovulatory bleeding. Int J Gynaecol Obstet. 2001;72:263-71.

Apgar B, Kaufman A, George-Nwogu U, Kittendorf A. Treatment of Menorrhagia. Am Fam Phy. 2007 Jun;75(12); 1813-1819.9.

Armour M, Ee CC, Naidoo D, Ayati Z, Chalmers KJ, Steel KA, de Manincor MJ, Delshad E. Exercise for dysmenorrhoea. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD004142. DOI: 10.1002/14651858.CD004142.pub4.

Balık, G., Ustüner, I., Kağıtcı, M., & Sahin, F. K. (2014). Is there a relationship between mood disorders and dysmenorrhea? Journal of Pediatric and Adolescent Gynecology, 27(6), 371–374. https://doi.org/10.1016/j.jpag.2014.01.108

Carl J, Hill DA. Preconception counseling: make it part of the annual exam. J Fam Pract. 2009 Jun;58(6):307-14.

Casey PM, Long ME, Marnach ML. Abnormal cervical appearance: what to do, when to worry?. Mayo Clin Proc. 2011;86(2):147–151. doi:10.4065/mcp.2010.0512

Centers for Disease Control. Routine Measles, Mumps, and Rubella Vaccination. Available at: https://www.cdc.gov/vaccines/vpd/mmr/hcp/recommendations.html. Accessed 12/31/2019.

Cope, E. Drugs (1980) 19: 342. https://doi.org/10.2165/00003495-198019050-00003

Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. 2006 Aug;108(2):428-41.

Eltoukhi H, Modi M, Weston M, Armstrong A, Stewart E. The health disparities of uterine fibroid tumors for African American women: a public health issue. Am J Obstet Gynecol. March 2014;210(3):194-9.

Fadhlaoui A, Ben Hassouna J, Khrouf M, Zhioua F, Chaker A. Endometrial adenocarcinoma in a 27-year-old woman. Clin Med Insights Case Rep. 2010;3:31–39.

Ferrero S; Abbamonte LH; Giordano M; Parisi M; Ragni N; Remorgida V. Uterine myomas, dyspareunia, and sexual function. Fertil Steril. 2006 Nov;86(5):1504-10.

Fisher WA, Black A. Contraception in Canada: a review of method choices, characteristics, adherence and approaches to counselling. CMAJ. 2007 Mar 27;176(7):953-61.

Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril. 2003;79(5);1194-8.

Grimes DA, Lopez LM, Manion C, Schulz KF. Cochrane systematic reviews of IUD trials: lessons learned. Contraception. 2007 Jun;75(6 Suppl):S55-9. Epub 2007 Feb 16.

Hay PE, Kerry SR, Normansell R, et al. Which sexually active young female students are most at risk of pelvic inflammatory disease? A prospective study. Sex Transm Infect. 2016;92(1):63–66. doi:10.1136/sextrans-2015-052063

Huyck KL; Panhuysen CI; Cuenco KT et al. The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters. Am J Obstet Gynecol. 2008 Feb;198(2):168.e1-9.

Iacovides S, Avidon I, and Baker FC. What we know about primary dysmenorrhea today: A critical review. Human Reproduction Update, 2015; 21(6):762–778. https://doi.org/10.1093/humupd/dmv039

Iacovides, S., Avidon, I., & Baker, F. C. (2015). What we know about primary dysmenorrhea today: A critical review. Human Reproduction Update, 21(6), 762–778. https://doi.org/10.1093/humupd/dmv039

James A, Matcher DB, Myers ER. Testing for von Willebrand disease in women with menorrhagia; a systematic review. Obstet Gynecol. 2004;104:381-8.

Johnson S. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: A clinical primer for practitioners. Obstet Gynecol. 2004;104(4).845-859.

Katz V, Lobo R, Lentz G, Gershenson D. Comprehensive Gynecology. 5th ed. St. Louis, MO: Mosby; 2007.

Korn AP, Hessol NA, Padian NS, et al. Risk factors for plasma cell endometritis among women with cervical Neisseria gonorrhoeae, cervical Chlamydia trachomatis, or bacterial vaginosis. Am J Obstet Gynecol. 1998 May;178(5):987-90.

Levgur M. Diagnosis of adenomyosis: a review. J Reprod Med. 2007 Mar;52(3):177-03.

Lippman SA; Warner M; Samuels S; Olive D; Vercellini P; Eskenazi B. Uterine fibroids and gynecologic pain symptoms in a population- based study. Fertil Steril 2003 Dec;80(6):1488-94.

Long WN. Pelvic Examination. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990. Chapter 177. Available from: https://www.ncbi.nlm.nih.gov/books/NBK286/

Magalhaes J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception. 2007;75(3):193-8.

Mansy, A. A. (2018). Does sublingual misoprostol reduce pain and facilitate IUD insertion in women with no previous vaginal delivery? A randomized controlled trial. Middle East Fertility Society Journal, 23(1), 72–76. https://doi.org/10.1016/J.MEFS.2017.08.007

Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003855.

Meredith SM, Sanchez-Ramos L, Kunitz AM. Diagnostic accuracy of transvaginal sonography for the diagnosis of adenomyosis: a systematic review and metaanalysis. Am J Obstet Gynecol. 2009;201(1):107.e1-6.

Morrow C, Naumberg E. Dysmenorrhea. Primary Care: Clinics in Office Practice. 2009 Mar;36(1):19-32

© 2020 Aquifer 8/9

https://www.ncbi.nlm.nih.gov/pubmed/23942040
https://www.ncbi.nlm.nih.gov/books/NBK286/

Proctor M, Farquhar C. Diagnosis and management of dysmenorrhea. BMJ. 2006 May 13;332(7550):1134-8

Proctor ML, Latthe PM, Farquhar CM, Khan KS, Johnson NP. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhea. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001896

Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptives (OCP) as treatment for primary dysmenorrhea. Cochrane Database System Rev. 2001(3):CD002120

Reid RL. Premenstrual Dysphoric Disorder (Formerly Premenstrual Syndrome) [Updated 2017 Jan 23]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Table 1, Diagnostic Criteria for Premenstrual Dysphoric Disorder (PMDD) Available from: https://www.ncbi.nlm.nih.gov/books/NBK279045/table/premenstrual- syndrom.table1diag/

SOGC clinical practice guidelines. Uterine fibroid embolization (UFE). Number 150. Int J Gynaecol Obstet. 2005 Jun;89(3):305-318.

Saslow, D., Solomon, D., Lawson, H. W., Killackey, M., Kulasingam, S. L., Cain, J. M., Myers, E. R. (2012). American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. Journal of Lower Genital Tract Disease, 16(3), 175–204. https://doi.org/10.1097/LGT.0b013e31824ca9d5

Savaris RF, Ross J, Fuhrich DG, Rodriguez‐Malagon N, Duarte RV. Antibiotic therapy for pelvic inflammatory disease (PID). Cochrane Database of Systematic Reviews 2013, Issue 1. Art. No.: CD010285. DOI: 10.1002/14651858.CD010285.

Shapley M, Jordan K, Croft PR. An epidemiological survey of symptoms of menstrual loss in a community. Br J Gen Pract2004;54:359.

Smorgick, N., & As-Sanie, S. (2018). Pelvic Pain in Adolescents. Seminars in Reproductive Medicine, 36(2), 116–122. https://doi.org/10.1055/s-0038-1676088

The American College of Obstetricians and Gynecologists. Marijuana and Pregnancy. FAQ 196, May 2018. Available at https://www.acog.org/Patients/FAQs/Marijuana-and-Pregnancy. Accessed October 10, 2019.

Uterine Fibroids – ACOG. (n.d.). Retrieved October 23, 2019, from https://www.acog.org/Patients/FAQs/Uterine-Fibroids

Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Res. 2019;8:F1000 Faculty Rev-283. Published 2019 Mar 13. doi:10.12688/f1000research.17242.1

Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2004;104(2):393–406.

© 2020 Aquifer 9/9

https://www.ncbi.nlm.nih.gov/books/NBK279045/table/premenstrual-syndrom.table1diag/
https://www.acog.org/Patients/FAQs/Marijuana-and-Pregnancy
https://www.acog.org/Patients/FAQs/Uterine-Fibroids
  • Family Medicine 32: 33-year-old female with painful periods
    • Learning Objectives
    • Knowledge
      • Primary Dysmenorrhea Definition, Prevalence, and Risk Factors
      • Gender
      • Gender and Sexual Identity Questions
      • Questioning about Pregnancy History
      • Normal Pelvic Exam Findings
      • Menorrhagia
      • Premenstrual Dysphoric Disorder DSM-5 Diagnostic Criteria
      • Preconception Counseling
      • Safety and Mental Health
    • Management
      • Primary Dysmenorrhea: Presentation and Treatment
      • Treatment for Leiomyomas and Associated Symptoms
      • Hormonal Birth Control Therapies
      • Premenstrual Syndrome Treatment
      • Progesterone-Releasing IUD Placement: Contraindications / Complications
    • Studies
      • Evaluation of Differential of Secondary Dysmenorrhea / Menorrhagia
    • Clinical Reasoning
      • Differential of Secondary Dysmenorrhea / Menorrhagia
      • More Common Diagnoses:
      • Less Common Diagnoses:
    • References